Spondyloarthritis & psoriatic arthritis
Improvement in spinal pain at night and its impact on long-term outcomes in radiographic axial spondyloarthritis: Results from Ixekizumab COAST-V randomised trial
Authors' conclusion
A larger proportion of patients treated with IXE Q4W achieved rapid and clinically meaningful improvement in spinal pain at night versus placebo, with improvements maintained up to W52. Achieving a CII in spinal pain at night at W16 was associated with improved disease activity, functioning, PROs, and QoL at W16 and W52.
Study context
- Population
- Patients with radiographic axial spondyloarthritis (r-axSpA) naïve to biological disease-modifying anti-rheumatic drug (bDMARD)
- Comparison
- Ixekizumab (IXE) Q4W vs ADA Q2W vs placebo; Clinically important improvement (CII) vs no CII in spinal pain at night at W16
- Primary endpoint
- CII (≥3-point improvement) in spinal pain at night
- Follow-up
- Up to W16
Methodological detailsphase 3, 52 W
- Phase 3
- 52 W
Primary result
As reported in the abstract
Further findings
ASDAS <2.1 among IXE Q4W patients achieving CII at W16 · W16 and W52
%
- ASDAS <2.1 at W16
- 58.8
- ASDAS <2.1 at W52
- 66.7
ASDAS <1.3 among IXE Q4W patients achieving CII at W16 · W16 and W52
%
- ASDAS <1.3 at W16
- 25.5
- ASDAS <1.3 at W52
- 29.4
Disease activity, functioning and health-related quality of life (QoL) in patients achieving CII at W16 · W16 and W52
- Improvement for patients who achieved a CII in spinal pain at night at W16
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →